The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy

Ivanov S.V.; Voronova E.I.

doi:https://doi.org/10.17116/jnevro2021121091139

Close metadata

Recommended articles:

The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48

A role of transcription factors in pathogenic processes associated with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Metabolic syndrome and antipsychotic therapy of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170

Neuronal models based on olfactory epithelial cells in the study of the pathogenesis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):20-25

Pathogenetic interrelations of hypogonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34

Clinical and immunological relationships in patients with early schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Abstract:

Cariprazine is a newer 3rd generation antipsychotic acting as partial agonist for dopamine receptors with unique higher affinity for D3 than D2 receptors. This review article summarizes key data from preclinical and clinical studies of cariprazine including pharmacodynamics, pharmacokinetics, clinical efficacy and safety/acceptability in acute short-term and long-term maintenance and relapse prevention therapy in patients with schizophrenia. Efficacy and safety of cariprazine in patients schizophrenia with predominantly negative symptoms resistant to previous antipsychotic therapy is discussed as well.

Keywords:

schizophrenia

positive disorders

negative disorders

therapy

antipsychotics

cariprazine

Authors:

Ivanov S.V.

Mental Health Research Center

ORCID: 0000-0001-9532-7150

Voronova E.I.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

ORCID: 0000-0001-6605-4851

Received:

03.08.2021

Accepted:

06.08.2021

Close metadata

References:

Smulevich AB. Negative Disorders in Schizophrenia. M.: MEDpress Inform Publishers; 2021. (In Russ.).
Stępnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules. 2018;23(8):2087. https://doi.org/10.3390/molecules23082087
Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29-41. https://doi.org/10.1177/2045125316672136
Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123-127. https://doi.org/10.1017/S1092852916000043
Bykov YuV, Bekker RA, Morozov PV. The efficacy of cariprazine in the treatment of schizophrenia, especially with prominent or predominant negative symptoms. Psychiatry and Psychopharmacotherapy. 2018;5:27-37. (In Russ.).
Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat. 2018;14:2563-2577. https://doi.org/10.2147/NDT.S159704
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2-3):450-457. https://doi.org/10.1016/j.schres.2013.11.041
Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. J Clin Psychopharmacol. 2015;35(4):367-373. https://doi.org/10.1097/JCP.0000000000000346
Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574-1582. PMID: 26717533. https://doi.org/10.4088/JCP.15m09997
Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016;31(2):61-68. https://doi.org/10.1097/YIC.0000000000000110
Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017;32(6):309-318. https://doi.org/10.1097/YIC.0000000000000189
Isjanovski V, Naumovska A, Bonevski D, Novotni A. Validation of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) Among Patients with Schizophrenia. Open Access Maced J Med Sci. 2016;4(1):65-69. Epub 2016 Jan 11. PMID: 27275332; PMCID: PMC4884255. https://doi.org/10.3889/oamjms.2016.015
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2-3):264-271. Epub 2016 Jul 15. Erratum in: Schizophr Res. 2018;192:493. https://doi.org/10.1016/j.schres.2016.06.030
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017;234(2):199-209. https://doi.org/10.1007/s00213-016-4450-3
Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23(1):39-50. https://doi.org/10.1017/S1092852917000220
Earley W, Guo H, Luchini R. Modified cariprazine relapse prevention clinical trial results. Schizophr Res. 2018;199:452-453. https://doi.org/10.1016/j.schres.2018.04.016
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker W, Nasrallah HA. Corrigendum to «Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial» [Schizophr. Res. 176 (2016) 264-271]. Schizophr Res. 2018;192:493. Epub 2017 Apr 18. Erratum for: Schizophr Res. 2016;176(2-3):264-271. https://doi.org/10.1016/j.schres.2017.04.020
Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056. https://doi.org/10.4088/jcp.v64n0910
Fleischhacker W, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, Carson WH, Sanchez R, Nyilas M, Weiller E. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. Int J Neuropsychopharmacol. 2017;20(1):11-21. https://doi.org/10.1093/ijnp/pyw076
Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD. Olanzapine Relapse Prevention Study Group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 2003;23(6):582-594. https://doi.org/10.1097/01.jcp.0000095348.32154.ec
Rui Q, Wang Y, Liang S, Liu Y, Wu Y, Wu Q, Nuamah I, Gopal S. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:45-53. https://doi.org/10.1016/j.pnpbp.2014.02.007
Peuskens J, Trivedi J, Malyarov S, Brecher M, Svensson O, Miller F, Persson I, Meulien D. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont). 2007;4(11):34-50.
Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349-355. https://doi.org/10.4088/JCP.10m06306
Arato M, O’Connor R, Meltzer HY. ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207-215. https://doi.org/10.1097/00004850-200209000-00001
Tandon R, Cucchiaro J, Phillips D, Hernandez D, Mao Y, Pikalov A, Loebel A. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol. 2016;30(1):69-77. https://doi.org/10.1177/0269881115620460
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker W. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103-1113. https://doi.org/10.1016/S0140-6736(17)30060-0
Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1-9. https://doi.org/10.1016/j.eurpsy.2019.01.015
Smulevich AB, Ivanov SV, Yakhin KK, Voronova EI, Kharkova GS, Skurygina EI, Konohova MV, Beybalaeva TZ, Katok AA. Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(12):67-72. (In Russ.). https://doi.org/10.17116/jnevro202012012167
Rancans E, Dombi ZB, Mátrai P, Barabássy Á, Sebe B, Skrivele I, Németh G. The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. Int Clin Psychopharmacol. 2021;36(3):154-161. https://doi.org/10.1097/YIC.0000000000000351
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. https://doi.org/10.2147/TCRM.S117321
Citrome L. The ABC’s of dopamine receptor partial agonists — aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211-1220. https://doi.org/10.1111/ijcp.12752
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29(9):971-985. https://doi.org/10.1016/j.euroneuro.2019.06.008
Demyttenaere K, Detraux J, Racagni G, Vansteelandt K. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis. CNS Drugs. 2019;33(6):549-566. https://doi.org/10.1007/s40263-019-00625-3
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77. https://doi.org/10.1016/S2215-0366(19)30416-X
Mosolov SN, Yaltonskaya PA. Algorithm for the Treatment of Primary Negative Symptoms in Schizophrenia. Sovrem ter psih rasstrojstv. 2020;2:2-10. (In Russ.). https://doi.org/10.21265/PSYPH.2020.26.17.001